DDInter1570 DDInter1477
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Dronedarone
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Ranolazine {u} (Compound) upregulates {v} (Gene) NR1H2
NR1H2 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Ranolazine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Ranolazine {u} (Compound) upregulates {v} (Gene) NR1H2
NR1H2 {u} (Gene) is upregulated by {v} (Compound) Fenofibrate
Fenofibrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Ranolazine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Miconazole
Miconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Ranolazine {u} (Compound) causes {v} (Side Effect) Urinary retention
Urinary retention {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bedaquiline
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Ranolazine {u} (Compound) causes {v} (Side Effect) Urinary retention
Urinary retention {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Ranolazine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Pirfenidone
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Ranolazine (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Ranolazine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Ranolazine (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is upregulated by Fenofibrate (Compound) and Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Ranolazine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Miconazole (Compound) and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Ranolazine (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound) and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Ranolazine (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Ranolazine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Pirfenidone